Circassia USA Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Circassia USA's estimated annual revenue is currently $2.6M per year.(i)
  • Circassia USA's estimated revenue per employee is $201,000

Employee Data

  • Circassia USA has 13 Employees.(i)
  • Circassia USA grew their employee count by -32% last year.

Circassia USA's People

NameTitleEmail/Phone
1
Regional VP, EMEA and Partner MarketsReveal Email/Phone
2
VP, Americas Clinical BusinessReveal Email/Phone
3
VP Product Development, Quality, Regulatory & MedicalReveal Email/Phone
4
VP Information TechnologyReveal Email/Phone
5
SVP, Global Human ResourcesReveal Email/Phone
6
SVP, Americas & Global Research BusinessReveal Email/Phone
7
Head MarketingReveal Email/Phone
8
Head Quality and RegulatoryReveal Email/Phone
9
Controller - USReveal Email/Phone
10
Medical Director ROW excluding USAReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.8M294%N/AN/A
#2
$3.2M160%N/AN/A
#3
$83.2M4147%N/AN/A
#4
$31M15456%N/AN/A
#5
$66.6M2650%$35MN/A
#6
$10.9M546%N/AN/A
#7
$6.8M34-6%N/AN/A
#8
$165.7M21614%$250.7MN/A
#9
$26.5M132-11%$637.8KN/A
#10
$49.4M2466%N/AN/A
Add Company

What Is Circassia USA?

Circassia Pharmaceuticals Inc (Circassia USA), headquartered in Morrisville, NC, is a specialty pharmaceutical and medical device company focused on respiratory disease. We employ more than 200 people in the United States. Our vision is to partner with the healthcare community and provide patients with access to medical devices and therapies that help them live the life they deserve. We?re building a company that will lead to improvements for customers, healthcare providers, and employees. Ours is an open culture built by, and for, energized, dedicated, passionate, transparent, and resourceful people. Circassia USA is a wholly-owned subsidiary of Circassia Pharmaceuticals plc which is headquartered in Oxford, United Kingdom. Circassia Pharmaceuticals plc is a world-class specialty pharmaceutical business focused on respiratory disease. Circassia Pharmaceuticals plc sells its products directly to specialists in the United States, United Kingdom, China, Germany, and in a wide range of other countries through its network of partners. For more information about Circassia and our products, please visit https://www.circassia.com.

keywords:N/A

N/A

Total Funding

13

Number of Employees

$2.6M

Revenue (est)

-32%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Circassia USA News

2022-04-17 - Circassia Inc. Significantly Expands Reach of NIOX® FeNO ...

Circassia's NIOX® products are used to improve asthma patient outcomes, ... NIOX® is the leading FeNO testing device in the U.S.,...

2022-04-17 - Allergy Vaccine Market Size, Scope And Outlook | Circassia ...

New Jersey, United States – The study is a professional and comprehensive assessment of the Allergy ... Circassia Pharmaceuticals, Aimmue Therapeutics, Inc,...

2022-03-22 - The Women Keeping Circassian Cuisine Alive in Jordan

The restaurant is a part of the larger Circassian Charity Association in ... the United States, Egypt, Lebanon, the Balkans, and Germany.

2021-03-24 - Circassia : PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DECEMBER 2020

PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DECEMBER 2020 Oxford, UK - 24 March 2021: Circassia Group plc ('Circassia' or the 'Company' and, together with its subsidiaries, the 'Group') (LSE: CIR) today announces its audited results for the year ended 31 December 2020 and a post-period update. Fi ...

2021-03-24 - CIRCASSIA GROUP PLC Circassia : PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DECEMBER 2020

PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DECEMBER 2020 Oxford, UK - 24 March 2021: Circassia Group plc ('Circassia' or the 'Company' and, together with its subsidiaries, the 'Group') (LSE: CIR) today announces its audited results for the year ended 31 December 2020 and a post-period update. Fi ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.6M138%$148.9M
#2
$1.9M13-54%N/A
#3
N/A14-12%N/A
#4
$1.2M140%N/A
#5
$2.1M1417%N/A